{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:23:28Z","timestamp":1788985408283,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Self-funded Research Project in Western Medicine, Health Commission of Guangxi, China","award":["Z-D20231663"],"award-info":[{"award-number":["Z-D20231663"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11096-025-01980-6","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T12:35:50Z","timestamp":1754742950000},"page":"1821-1829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database"],"prefix":"10.1007","volume":"47","author":[{"given":"Haowen","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"1980_CR1","unstructured":"World Health Organization 2016. Global Report on Psoriasis. ISBN 978-92-4-156518-9. https:\/\/iris.who.int\/handle\/10665\/204417. Accessed 14 Mar 2025."},{"key":"1980_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"1980_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:205\u201312. https:\/\/doi.org\/10.1111\/jdv.13854.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1980_CR4","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397:1301\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6.","journal-title":"Lancet"},{"key":"1980_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/17512433.2017.1293519","volume":"10","author":"R Vangipuram","year":"2017","unstructured":"Vangipuram R, Alikhan A. Apremilast for the management of moderate to severe plaque psoriasis. Expert Rev Clin Pharmacol. 2017;10:349\u201360. https:\/\/doi.org\/10.1080\/17512433.2017.1293519.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1980_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/jdv.16980","volume":"35","author":"T Tsakok","year":"2021","unstructured":"Tsakok T, Rispens T, Spuls P, et al. Immunogenicity of biologic therapies in psoriasis: myths, facts and a suggested approach. J Eur Acad Dermatol Venereol. 2021;35:329\u201337. https:\/\/doi.org\/10.1111\/jdv.16980.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1980_CR7","doi-asserted-by":"publisher","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11:eaaw1736. https:\/\/doi.org\/10.1126\/scitranslmed.aaw1736.","journal-title":"Sci Transl Med."},{"key":"1980_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2217\/imt-2021-0096","volume":"13","author":"M Gonciarz","year":"2021","unstructured":"Gonciarz M, Pawlak-Bu\u015b K, et al. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy. 2021;13:1135\u201350. https:\/\/doi.org\/10.2217\/imt-2021-0096.","journal-title":"Immunotherapy"},{"key":"1980_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp K, Gordon K, Tha\u00e7i D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379:1313\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1806382.","journal-title":"N Engl J Med"},{"key":"1980_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88:29\u201339. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.002.","journal-title":"J Am Acad Dermatol"},{"key":"1980_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88:40\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.061.","journal-title":"J Am Acad Dermatol"},{"key":"1980_CR12","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/jdv.19925","volume":"38","author":"B Strober","year":"2024","unstructured":"Strober B, Blauvelt A, Warren RB, et al. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024;38:1543\u201354. https:\/\/doi.org\/10.1111\/jdv.19925.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1980_CR13","unstructured":"International Council for Harmonisation. Pharmacovigilance Planning E2E. https:\/\/www.ich.org\/page\/efficacy-guidelines. Accessed 3 Jun 2025."},{"key":"1980_CR14","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf. Accessed 3 Jun 2025."},{"key":"1980_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clml.2019.08.008","volume":"20","author":"K Anand","year":"2020","unstructured":"Anand K, Burns EA, Ensor J, et al. Mycobacterial infections with ruxolitinib: a retrospective pharmacovigilance review. Clin Lymphoma Myeloma Leuk. 2020;20:18\u201323. https:\/\/doi.org\/10.1016\/j.clml.2019.08.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1980_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70030","volume":"33","author":"J Yuan","year":"2024","unstructured":"Yuan J, Lu H, Zuo X, et al. Adverse event assessment of upadacitinib: a pharmacovigilance study based on the FAERS database. Pharmacoepidemiol Drug Saf. 2024;33: e70030. https:\/\/doi.org\/10.1002\/pds.70030.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1980_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/14740338.2023.2248872","volume":"22","author":"L Wang","year":"2023","unstructured":"Wang L, Zhao B. Janus kinase inhibitor-Tofacitinib associated with pemphigus: an analysis of the FDA adverse event reporting system data. Expert Opin Drug Saf. 2023;22:1317\u201320. https:\/\/doi.org\/10.1080\/14740338.2023.2248872.","journal-title":"Expert Opin Drug Saf"},{"key":"1980_CR18","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Xiao K, Ottaviani S, et al. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020;19:1505\u201311. https:\/\/doi.org\/10.1080\/14740338.2020.1799975.","journal-title":"Expert Opin Drug Saf"},{"key":"1980_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s11096-023-01634-5","volume":"45","author":"T Liu","year":"2023","unstructured":"Liu T, Gao R, Li L, et al. Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System. Int J Clin Pharm. 2023;45:1483\u201391. https:\/\/doi.org\/10.1007\/s11096-023-01634-5.","journal-title":"Int J Clin Pharm"},{"key":"1980_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323. https:\/\/doi.org\/10.1002\/pds.1001.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1980_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1980_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321. https:\/\/doi.org\/10.1007\/s002280050466.","journal-title":"Eur J Clin Pharmacol"},{"key":"1980_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/00031305.1999.10474457","volume":"53","author":"RT O'Neill","year":"1999","unstructured":"O\u2019Neill RT, Szarfman A. [Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system]: discussion. Am Stat. 1999;53:190\u20136. https:\/\/doi.org\/10.1080\/00031305.1999.10474457.","journal-title":"Am Stat"},{"key":"1980_CR24","unstructured":"European Medicines Agency. MedDRA important medical event terms list-version 27.1. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-system-overview. Accessed 17 Mar 2025."},{"key":"1980_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","volume":"35","author":"VR Cornelius","year":"2012","unstructured":"Cornelius VR, Sauzet O, Evans SJ. A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. Drug Saf. 2012;35:599\u2013610. https:\/\/doi.org\/10.2165\/11599740-000000000-00000.","journal-title":"Drug Saf"},{"key":"1980_CR26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, et al. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36:995\u20131006. https:\/\/doi.org\/10.1007\/s40264-013-0061-7.","journal-title":"Drug Saf"},{"key":"1980_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita S, Hosomi K, Yokoyama S, et al. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J Clin Pharm Ther. 2020;45:65\u201371. https:\/\/doi.org\/10.1111\/jcpt.13024.","journal-title":"J Clin Pharm Ther"},{"key":"1980_CR28","unstructured":"21 CFR \u00a7 600.80 - Postmarketing reporting of adverse experiences. https:\/\/www.govinfo.gov\/app\/details\/CFR-2023-title21-vol7\/CFR-2023-title21-vol7-sec600-80\/context. Accessed 14 Mar 2025."},{"key":"1980_CR29","unstructured":"Bristol Myers Squibb. SOTYKTU\u2122 (deucravacitinib) tablets, for oral use: US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214958s000lbl.pdf. Accessed 14 Mar 2025."},{"key":"1980_CR30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/bjd\/ljae014","volume":"190","author":"M Lebwohl","year":"2024","unstructured":"Lebwohl M, Warren RB, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol. 2024;190:668\u201379. https:\/\/doi.org\/10.1093\/bjd\/ljae014.","journal-title":"Br J Dermatol"},{"key":"1980_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/cts.13435","volume":"16","author":"IM Catlett","year":"2023","unstructured":"Catlett IM, Aras U, Hansen L, et al. First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin Transl Sci. 2023;16:151\u201364. https:\/\/doi.org\/10.1111\/cts.13435.","journal-title":"Clin Transl Sci"},{"key":"1980_CR32","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1111\/all.15612","volume":"78","author":"T Hanschmann","year":"2023","unstructured":"Hanschmann T, Francuzik W, D\u00f6lle-Bierke S, et al. Different phenotypes of drug-induced anaphylaxis-Data from the European Anaphylaxis Registry. Allergy. 2023;78:1615\u201327. https:\/\/doi.org\/10.1111\/all.15612.","journal-title":"Allergy"},{"key":"1980_CR33","doi-asserted-by":"publisher","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","volume":"13","author":"V Cardona","year":"2020","unstructured":"Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13:100472. https:\/\/doi.org\/10.1016\/j.waojou.2020.100472.","journal-title":"World Allergy Organ J"},{"key":"1980_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.7326\/0003-4819-124-1_part_1-199601010-00005","volume":"124","author":"S Murakami","year":"1996","unstructured":"Murakami S, Mizobuchi M, Nakashiro Y, et al. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med. 1996;124:27\u201330. https:\/\/doi.org\/10.7326\/0003-4819-124-1_part_1-199601010-00005.","journal-title":"Ann Intern Med"},{"key":"1980_CR35","unstructured":"U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed 3 Jun 2025."},{"key":"1980_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002236","volume":"8","author":"TW Kragstrup","year":"2022","unstructured":"Kragstrup TW, Glintborg B, Svensson AL, et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8: e002236. https:\/\/doi.org\/10.1136\/rmdopen-2022-002236.","journal-title":"RMD Open"},{"key":"1980_CR37","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","volume":"22","author":"RMC Di Martino","year":"2023","unstructured":"Di Martino RMC, Maxwell BD, Pirali T. Deuterium in drug discovery: progress, opportunities and challenges. Nat Rev Drug Discov. 2023;22:562\u201384. https:\/\/doi.org\/10.1038\/s41573-023-00703-8.","journal-title":"Nat Rev Drug Discov"},{"key":"1980_CR38","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"62","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine Kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62:8973\u201395. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00444.","journal-title":"J Med Chem"},{"key":"1980_CR39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","volume":"20","author":"MM Attwood","year":"2021","unstructured":"Attwood MM, Fabbro D, Sokolov AV, et al. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20:839\u201361. https:\/\/doi.org\/10.1038\/s41573-021-00252-y.","journal-title":"Nat Rev Drug Discov"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01980-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01980-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01980-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:07:42Z","timestamp":1763554062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01980-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1980"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01980-6","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was not required for this study as it was a retrospective analysis of FAERS database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}